Annie Oh1, Melanie L Foster1, Jonathan G Williams1, Chaowen Zheng2, Hongyu Ru3, Katharine F Lunn1, Freya M Mowat1. 1. Department of Clinical Sciences, College of Veterinary Medicine, North Carolina State University, Raleigh, North Carolina. 2. Department of Statistics, North Carolina State University, Raleigh, North Carolina. 3. Department of Population Health and Pathobiology, College of Veterinary Medicine, North Carolina State University, Raleigh, North Carolina.
Abstract
OBJECTIVE: To identify discriminating factors, using clinical ophthalmic examination findings and routine laboratory testing, that differentiate dogs with early sudden acquired retinal degeneration (SARDS; vision loss <6 weeks' duration), age- and breed-matched control dogs, and dogs with pituitary-dependent hyperadrenocorticism (PDH). ANIMALS: Client-owned dogs: 15 with SARDS with <6 weeks duration of vision loss, 14 age- and breed-matched control dogs, and 13 dogs with confirmed PDH. PROCEDURES: Dogs underwent ophthalmic examination, electroretinography (ERG) fundus photography, and spectral-domain optical coherence tomography (SD-OCT) in addition to physical examination, urinalysis, serum biochemistry, complete blood count, and adrenocorticotrophic hormone (ACTH) stimulation testing. Statistical analysis was performed using receiver operating curve area under the curve analysis, principal component analysis with sparse partial least squares analysis, and one-way ANOVA. RESULTS: Dogs with SARDS all had absent vision and ERG a- and b-waves. SD-OCT demonstrated that dogs with SARDS had significantly thicker inner retina, thinner outer nuclear layer, and thicker photoreceptor inner/outer segment measurements than either controls or dogs with PDH. Discriminating laboratory parameters between dogs with SARDS and PDH with high specificity included post-ACTH serum cortisol (<19.3 μg/dL), AST:ALT ratio (>0.343), and urine specific gravity (>1.030). CONCLUSIONS AND CLINICAL RELEVANCE: We have identified significant discriminators between SARDS and PDH. This work provides the basis for future studies that could identify and examine dogs with SARDS prior to vision loss, which may extend the potential therapeutic window for SARDS.
OBJECTIVE: To identify discriminating factors, using clinical ophthalmic examination findings and routine laboratory testing, that differentiate dogs with early sudden acquired retinal degeneration (SARDS; vision loss <6 weeks' duration), age- and breed-matched control dogs, and dogs with pituitary-dependent hyperadrenocorticism (PDH). ANIMALS: Client-owned dogs: 15 with SARDS with <6 weeks duration of vision loss, 14 age- and breed-matched control dogs, and 13 dogs with confirmed PDH. PROCEDURES: Dogs underwent ophthalmic examination, electroretinography (ERG) fundus photography, and spectral-domain optical coherence tomography (SD-OCT) in addition to physical examination, urinalysis, serum biochemistry, complete blood count, and adrenocorticotrophic hormone (ACTH) stimulation testing. Statistical analysis was performed using receiver operating curve area under the curve analysis, principal component analysis with sparse partial least squares analysis, and one-way ANOVA. RESULTS:Dogs with SARDS all had absent vision and ERG a- and b-waves. SD-OCT demonstrated that dogs with SARDS had significantly thicker inner retina, thinner outer nuclear layer, and thicker photoreceptor inner/outer segment measurements than either controls or dogs with PDH. Discriminating laboratory parameters between dogs with SARDS and PDH with high specificity included post-ACTH serum cortisol (<19.3 μg/dL), AST:ALT ratio (>0.343), and urine specific gravity (>1.030). CONCLUSIONS AND CLINICAL RELEVANCE: We have identified significant discriminators between SARDS and PDH. This work provides the basis for future studies that could identify and examine dogs with SARDS prior to vision loss, which may extend the potential therapeutic window for SARDS.
Authors: Elisa Mischi; Petr Soukup; Christine D Harman; Kazuya Oikawa; Malwina E Kowalska; Sonja Hartnack; Gillian J McLellan; András M Komáromy; Simon A Pot Journal: Vet Ophthalmol Date: 2022-05-25 Impact factor: 1.444
Authors: Marianna Bacellar-Galdino; Fabiano Montiani-Ferreira; Andre Tavares Somma; Ricardo Guilherme D'Otaviano de Castro Vilani; Ivan Roque de Barros Filho Journal: Vet World Date: 2020-05-08